These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 27926486)

  • 1. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
    Perez EM; Foley J; Tison T; Silva R; Ogembo JG
    Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
    Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
    Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
    Cui X; Snapper CM
    Front Immunol; 2021; 12():734471. PubMed ID: 34691042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV.
    Barasa AK; Ye P; Phelps M; Arivudainambi GT; Tison T; Ogembo JG
    Oncotarget; 2017 May; 8(21):34481-34497. PubMed ID: 28404899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
    Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
    Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
    Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
    Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
    Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
    Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
    Front Immunol; 2018; 9():932. PubMed ID: 29765376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
    Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
    Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
    Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
    J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
    Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
    Kong XW; Zhang X; Bu GL; Xu HQ; Kang YF; Sun C; Zhu QY; Ma RB; Liu Z; Zeng YX; Zeng MS; Hu ZL
    J Virol; 2022 May; 96(9):e0033622. PubMed ID: 35404082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice.
    Ogembo JG; Muraswki MR; McGinnes LW; Parcharidou A; Sutiwisesak R; Tison T; Avendano J; Agnani D; Finberg RW; Morrison TG; Fingeroth JD
    J Transl Med; 2015 Feb; 13():50. PubMed ID: 25885535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a multiepitope plasmid DNA encoding T and B lymphocyte epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a vaccine in mice.
    Li W; Chen Q; Lin Q; Lv Y; Feng J; Liu J; Xu W; Chen S; Zhu X; Zhang L
    Protein Pept Lett; 2013 Oct; 20(10):1136-43. PubMed ID: 23688153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
    J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
    Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
    Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge.
    Cui X; Cao Z; Ishikawa Y; Cui S; Imadome KI; Snapper CM
    Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33808755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cytoplasmic Tail Domain of Epstein-Barr Virus gH Regulates Membrane Fusion Activity through Altering gH Binding to gp42 and Epithelial Cell Attachment.
    Chen J; Jardetzky TS; Longnecker R
    mBio; 2016 Nov; 7(6):. PubMed ID: 27935841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.
    Heeke DS; Lin R; Rao E; Woo JC; McCarthy MP; Marshall JD
    Vaccine; 2016 May; 34(23):2562-9. PubMed ID: 27085175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.